Recommendation of the President – Cabomety (cabozantinib)
On 16 July 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 69/2024 on the evaluation of the drug Cabomety (cabozantinib) in combination with nivolumab within the framework of the drug program “Treatment of patients with renal cell carcinoma (ICD-10: C64)”